WHAT IS DELSTRIGO?
+

DELSTRIGO is a complete, one-pill prescription HIV medicine used to treat human immunodeficiency virus-1 (HIV-1) infection in adults who have not taken HIV-1 medicines before. HIV is the virus that causes AIDS (Acquired Immune Deficiency Syndrome).

 

You May Be Able to Lower Your HIV Viral Load to Undetectable
You May Be Able to Lower Your HIV Viral Load to Undetectable

ABOUT DELSTRIGO

WHAT IT DOES

DELSTRIGO may help lower your viral load to undetectable.

In a 48-week study of adults who were new to HIV-1 treatment, the percentage of those who reached an undetectable viral load was:

84% when taking DELSTRIGO

VS

84% when taking Atripla
(another HIV-1 medicine)

DELSTRIGO may not have these effects in all patients.

DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) May Help Lower Your Viral Load to UndetectableIn a 48-Week Study of Adults Who Were New to HIV-1 Treatment, the Percentage of Those Who Reached an Undetectable Viral Load was 84% When Taking DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate)DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) May Help Lower Your Viral Load to UndetectableIn a 48-Week Study of Adults Who Were New to HIV-1 Treatment, the Percentage of Those Who Reached an Undetectable Viral Load was 84% When Taking DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate)
The Safety and Efficacy of DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) was Compared to Atripla Over 48 Weeks in Adults Who Were New to HIV-1 Treatment The Safety and Efficacy of DELSTRIGO™ (doravirine/lamivudine/tenofovir disoproxil fumarate) was Compared to Atripla Over 48 Weeks in Adults Who Were New to HIV-1 Treatment

HOW IT WAS STUDIED

The safety and efficacy of DELSTRIGO was compared to Atripla over 48 weeks in adults who were new to HIV-1 treatment.

364 adults took DELSTRIGO

364 adults took Atripla

Patients were assigned by chance to take one of the two treatment regimens, and neither the patient nor the healthcare providers taking part in the study knew which regimen they were taking.


 

 
TRUSTe Verified Privacy TRUSTe APEC Privacy

Copyright © 2019 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.

For United States, its territories, and Puerto Rico only. US-DOR-00181 09/19

Worsening of hepatitis B virus infection (HBV). If you have both HIV-1 and HBV and stop taking DELSTRIGO, your HBV may suddenly get worse. Do not stop taking DELSTRIGO without first talking to your healthcare provider, as they will need to monitor your health. Your doctor should test you for HBV infection before you start treatment with DELSTRIGO.